Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene Gel in Parapsoriasis
NCT00322296Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2001
- Primary completion
- Jul 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bexarotene in parapsoriasis, sponsored by Fox Chase Cancer Center. Primary endpoint: Composite Assessment of Index Lesion Disease Severity at 16 weeks. Started Apr 2001; status: terminated.
02
Drugs
bexarotene
03
Conditions
parapsoriasis
Beyond the preview
Go deeper on NCT00322296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322296.